Top

Published in:

01-12-2020 | Lung Cancer | Guideline

Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice

Authors: Monique Maas, Regina Beets-Tan, Jean-Yves Gaubert, Fernando Gomez Munoz, Paul Habert, Lisa G. Klompenhouwer, Paulo Vilares Morgado, Niklaus Schaefer, Francois H. Cornelis, Stephen B. Solomon, Denise van der Reijd, Jose Ignacio Bilbao

Published in: Insights into Imaging | Issue 1/2020

Abstract

Interventional radiology plays an important and increasing role in cancer treatment. Follow-up is important to be able to assess treatment success and detect locoregional and distant recurrence and recommendations for follow-up are needed. At ECIO 2018, a joint ECIO-ESOI session was organized to establish follow-up recommendations for oncologic intervention in liver, renal, and lung cancer. Treatments included thermal ablation, TACE, and TARE. In total five topics were evaluated: ablation in colorectal liver metastases (CRLM), TARE in CRLM, TACE and TARE in HCC, ablation in renal cancer, and ablation in lung cancer. Evaluated modalities were FDG-PET-CT, CT, MRI, and (contrast-enhanced) ultrasound. Prior to the session, five experts were selected and performed a systematic review and presented statements, which were voted on in a telephone conference prior to the meeting by all panelists. These statements were presented and discussed at the ECIO-ESOI session at ECIO 2018. This paper presents the recommendations that followed from these initiatives. Based on expert opinions and the available evidence, follow-up schedules were proposed for liver cancer, renal cancer, and lung cancer. FDG-PET-CT, CT, and MRI are the recommended modalities, but one should beware of false-positive signs of residual tumor or recurrence due to inflammation early after the intervention. There is a need for prospective preferably multicenter studies to validate new techniques and new response criteria. This paper presents recommendations that can be used in clinical practice to perform the follow-up of patients with liver, lung, and renal cancer who were treated with interventional locoregional therapies.

Swartz MK (2011) The PRISMA statement: a guideline for systematic reviews and meta-analyses. J Pediatr Health Care. 25(1):1–2PubMed

Gillams A, Goldberg N, Ahmed M et al (2015) Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontieres meeting 2013. Eur Radiol. 25(12):3438–3454

Frich L, Hagen G, Brabrand K et al (2007) Local tumor progression after radiofrequency ablation of colorectal liver metastases: evaluation of ablative margin and three-dimensional volumetric analysis. J Vasc Interv Radiol. 18(9):1134–1140

Schraml C, Clasen S, Schwenzer NF et al (2008) Diagnostic performance of contrast-enhanced computed tomography in the immediate assessment of radiofrequency ablation success in colorectal liver metastases. Abdom Imaging. 33(6):643–651

Kele PG, de Jong KP, van der Jagt EJ (2012) Increase in volume of ablation zones during follow-up is highly suggestive of ablation site recurrence in colorectal liver metastases treated with radiofrequency ablation. J Vasc Interv Radiol. 23(4):537–544PubMed

Wang X, Sofocleous CT, Erinjeri JP et al (2013) Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol. 36(1):166–175

Sotirchos VS, Petrovic LM, Gonen M et al (2016) Colorectal Cancer Liver Metastases: Biopsy of the Ablation Zone and Margins Can Be Used to Predict Oncologic Outcome. Radiology. 280(3):949–959

Meijerink MR, van Waesberghe JH, van der Weide L et al (2009) Early detection of local RFA site recurrence using total liver volume perfusion CT initial experience. Acad Radiol. 16(10):1215–1222

Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H (2006) Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol. 16(1):80–87PubMed

10.

Sahin DA, Agcaoglu O, Chretien C, Siperstein A, Berber E (2012) The utility of PET/CT in the management of patients with colorectal liver metastases undergoing laparascopic radiofrequency thermal ablation. Ann Surg Oncol. 19(3):850–855PubMed

11.

Travaini LL, Trifiro G, Ravasi L et al (2008) Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results. Eur J Nucl Med Mol Imaging. 35(7):1316–1322

12.

Nielsen K, van Tilborg AA, Scheffer HJ et al (2013) PET-CT after radiofrequency ablation of colorectal liver metastases: suggestions for timing and image interpretation. Eur J Radiol. 82(12):2169–2175

13.

Liu ZY, Chang ZH, Lu ZM, Guo QY (2010) Early PET/CT after radiofrequency ablation in colorectal cancer liver metastases: is it useful? Chin Med J (Engl). 123(13):1690–1694PubMed

14.

Khandani AH, Calvo BF, O'Neil BH, Jorgenson J, Mauro MA (2007) A pilot study of early 18F-FDG PET to evaluate the effectiveness of radiofrequency ablation of liver metastases. AJR Am J Roentgenol. 189(5):1199–1202PubMed

15.

Langenhoff BS, Oyen WJ, Jager GJ et al (2002) Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol. 20(22):4453–4458

16.

Kuehl H, Antoch G, Stergar H et al (2008) Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol. 67(2):362–371

17.

Kierans AS, Elazzazi M, Braga L et al (2010) Thermoablative treatments for malignant liver lesions: 10-year experience of MRI appearances of treatment response. AJR Am J Roentgenol. 194(2):523–529

18.

Sainani NI, Gervais DA, Mueller PR, Arellano RS (2013) Imaging after percutaneous radiofrequency ablation of hepatic tumors: Part 2. Abnormal findings. AJR Am J Roentgenol. 200(1):194–204PubMed

19.

Schraml C, Schwenzer NF, Clasen S et al (2009) Navigator respiratory-triggered diffusion-weighted imaging in the follow-up after hepatic radiofrequency ablation-initial results. J Magn Reson Imaging. 29(6):1308–1316

20.

Eisele RM, Schumacher G, Lopez-Hanninen E, Neuhaus P (2007) Role of B-mode ultrasound screening in detection of local tumor recurrence in the first year after radiofrequency ablation in the liver. Cancer Detect Prev. 31(4):316–322PubMed

21.

Lewandowski RJ, Thurston KG, Goin JE et al (2005) 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol. 16(12):1641–1651

22.

Szyszko T, Al-Nahhas A, Canelo R et al (2007) Assessment of response to treatment of unresectable liver tumors with 90Y microspheres: value of FDG PET versus computed tomography. Nucl Med Commun. 28(1):15–20

23.

Sabet A, Meyer C, Aouf A et al (2015) Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. Eur J Nucl Med Mol Imaging. 42(3):370–376

24.

Michl M, Lehner S, Paprottka PM et al (2016) Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer. J Nucl Med. 57(3):355–360

25.

Hipps D, Ausania F, Manas DM, Rose JD, French JJ (2013) Selective Interarterial Radiation Therapy (SIRT) in Colorectal Liver Metastases: How Do We Monitor Response? HPB Surg. 2013:570808PubMedPubMedCentral

26.

Shady W, Sotirchos VS, Do RK et al (2016) Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres. AJR Am J Roentgenol. 207(3):661–670

27.

Reiner CS, Gordic S, Puippe G et al (2016) Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment. Cardiovasc Intervent Radiol. 39(3):400–408

28.

Schmeel FC, Simon B, Sabet A et al (2017) Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy. Eur Radiol. 27(3):966–975

29.

Barabasch A, Kraemer NA, Ciritsis A et al (2015) Diagnostic accuracy of diffusion-weighted magnetic resonance imaging versus positron emission tomography/computed tomography for early response assessment of liver metastases to Y90-radioembolization. Invest Radiol. 50(6):409–415

30.

Paris F, Fuks Z, Kang A et al (2001) Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science. 293(5528):293–297

31.

Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ (2002) Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging. 29(6):815–820PubMed

32.

Singh P, Anil G (2014) Yttrium-90 radioembolization of liver tumors: what do the images tell us? Cancer Imaging. 13(4):645–657PubMedPubMedCentral

33.

Nakazawa T, Kokubu S, Shibuya A et al (2007) Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol. 188(2):480–488

34.

Llovet JM, Di Bisceglie AM, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 100(10):698–711

35.

Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 30(1):52–60PubMed

36.

Chung WS, Lee KH, Park MS et al (2012) Enhancement patterns of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads on arterial phase CT images: a pilot retrospective study. AJR Am J Roentgenol. 199(2):349–359

37.

European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 56(4):908–943

38.

Takayasu K, Arii S, Matsuo N et al (2000) Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol. 175(3):699–704

39.

Galizia MS, Tore HG, Chalian H, Yaghmai V (2011) Evaluation of hepatocellular carcinoma size using two-dimensional and volumetric analysis: effect on liver transplantation eligibility. Acad Radiol. 18(12):1555–1560PubMed

40.

Yaghmai V, Miller FH, Rezai P, Benson AB 3rd, Salem R (2011) Response to treatment series: part 2, tumor response assessment--using new and conventional criteria. AJR Am J Roentgenol. 197(1):18–27PubMed

41.

Chalian H, Tochetto SM, Tore HG, Rezai P, Yaghmai V (2012) Hepatic tumors: region-of-interest versus volumetric analysis for quantification of attenuation at CT. Radiology. 262(3):853–861PubMed

42.

Kim S, Mannelli L, Hajdu CH et al (2010) Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging. 31(2):348–355

43.

Khan MA, Combs CS, Brunt EM et al (2000) Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 32(5):792–797

44.

Kamel IR, Bluemke DA, Eng J et al (2006) The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 17(3):505–512

45.

Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB (2010) MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 33(3):532–540PubMed

46.

Boas FE, Do B, Louie JD et al (2015) Optimal imaging surveillance schedules after liver-directed therapy for hepatocellular carcinoma. J Vasc Interv Radiol. 26(1):69–73

47.

Goshima S, Kanematsu M, Kondo H et al (2008) Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging. 27(4):834–839

48.

Yuan Z, Ye XD, Dong S et al (2010) Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma. Eur J Radiol. 75(1):e9-14.

49.

Taouli B, Johnson RS, Hajdu CH et al (2013) Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI. AJR Am J Roentgenol. 201(4):795–800

50.

Sabet A, Ahmadzadehfar H, Bruhman J et al (2014) Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET. Nuklearmedizin. 53(2):39–45

51.

Kim HJ, Kim TK, Kim PN et al (2006) Assessment of the therapeutic response of hepatocellular carcinoma treated with transcatheter arterial chemoembolization: comparison of contrast-enhanced sonography and 3-phase computed tomography. J Ultrasound Med. 25(4):477–486

52.

Moschouris H, Malagari K, Papadaki MG, Kornezos I, Matsaidonis D (2010) Contrast-enhanced ultrasonography of hepatocellular carcinoma after chemoembolisation using drug-eluting beads: a pilot study focused on sustained tumor necrosis. Cardiovasc Intervent Radiol. 33(5):1022–1027PubMed

53.

Finelli A, Ismaila N, Russo P (2017) Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 13(4):276–278PubMed

54.

Aron M, Gill IS (2005) Renal tumor ablation. Curr Opin Urol. 15(5):298–305PubMed

55.

Onik GM, Reyes G, Cohen JK, Porterfield B (1993) Ultrasound characteristics of renal cryosurgery. Urology. 42(2):212–215PubMed

56.

Ho VB, Allen SF, Hood MN, Choyke PL (2002) Renal masses: quantitative assessment of enhancement with dynamic MR imaging. Radiology. 224(3):695–700PubMed

57.

Zagoria RJ, Traver MA, Werle DM, Perini M, Hayasaka S, Clark PE (2007) Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol. 189(2):429–436PubMed

58.

Krokidis ME, Orsi F, Katsanos K, Helmberger T, Adam A (2017) CIRSE Guidelines on Percutaneous Ablation of Small Renal Cell Carcinoma. Cardiovasc Intervent Radiol. 40(2):177–191PubMed

59.

Russo U, Maestroni U, Papapietro RV et al. (2018) Imaging after radiofrequency ablation of renal tumors. Future Oncol 14(28):2915-2922.

60.

Atwell TD, Carter RE, Schmit GD et al (2012) Complications following 573 percutaneous renal radiofrequency and cryoablation procedures. J Vasc Interv Radiol. 23(1):48–54

61.

Gervais DA, Arellano RS, McGovern FJ, McDougal WS, Mueller PR (2005) Radiofrequency ablation of renal cell carcinoma: part 2, Lessons learned with ablation of 100 tumors. AJR Am J Roentgenol. 185(1):72–80PubMed

62.

Hiraoka K, Kawauchi A, Nakamura T, Soh J, Mikami K, Miki T (2009) Radiofrequency ablation for renal tumors: our experience. Int J Urol. 16(11):869–873PubMed

63.

Takaki H, Soga N, Kanda H et al (2014) Radiofrequency ablation versus radical nephrectomy: clinical outcomes for stage T1b renal cell carcinoma. Radiology. 270(1):292–299

64.

Atwell TD, Schmit GD, Boorjian SA et al (2013) Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. AJR Am J Roentgenol. 200(2):461–466

65.

Gervais DA, McGovern FJ, Wood BJ, Goldberg SN, McDougal WS, Mueller PR (2000) Radio-frequency ablation of renal cell carcinoma: early clinical experience. Radiology. 217(3):665–672PubMed

66.

Caviezel A, Terraz S, Schmidlin F, Becker C, Iselin CE (2008) Percutaneous cryoablation of small kidney tumors under magnetic resonance imaging guidance: medium-term follow-up. Scand J Urol Nephrol. 42(5):412–416PubMed

67.

Davenport MS, Caoili EM, Cohan RH et al (2009) MRI and CT characteristics of successfully ablated renal masses: Imaging surveillance after radiofrequency ablation. AJR Am J Roentgenol. 192(6):1571–1578

68.

Schirmang TC, Mayo-Smith WW, Dupuy DE, Beland MD, Grand DJ (2009) Kidney neoplasms: renal halo sign after percutaneous radiofrequency ablation--incidence and clinical importance in 101 consecutive patients. Radiology. 253(1):263–269PubMed

69.

Durack JC, Richioud B, Lyon J, Solomon SB (2014) Late emergence of contrast-enhancing fat necrosis mimicking tumor seeding after renal cryoablation. J Vasc Interv Radiol. 25(1):133–137PubMed

70.

Yang Q, Qi H, Zhang R et al (2017) Risk Factors for Local Progression after Percutaneous Radiofrequency Ablation of Lung Tumors: Evaluation Based on a Review of 147 Tumors. J Vasc Interv Radiol. 28(4):481–489

71.

Belfiore G, Moggio G, Tedeschi E et al (2004) CT-guided radiofrequency ablation: a potential complementary therapy for patients with unresectable primary lung cancer--a preliminary report of 33 patients. AJR Am J Roentgenol. 183(4):1003–1011

72.

Palussiere J, Lagarde P, Auperin A, Deschamps F, Chomy F, de Baere T (2015) Percutaneous lung thermal ablation of non-surgical clinical N0 non-small cell lung cancer: results of eight years' experience in 87 patients from two centers. Cardiovasc Intervent Radiol. 38(1):160–166PubMed

73.

Palussiere J, Marcet B, Descat E et al (2011) Lung tumors treated with percutaneous radiofrequency ablation: computed tomography imaging follow-up. Cardiovasc Intervent Radiol. 34(5):989–997

74.

Fanucchi O, Ambrogi MC, Aprile V et al (2016) Long-term results of percutaneous radiofrequency ablation of pulmonary metastases: a single institution experience. Interact Cardiovasc Thorac Surg. 23(1):57–64

75.

McDevitt JL, Mouli SK, Nemcek AA, Lewandowski RJ, Salem R, Sato KT (2016) Percutaneous Cryoablation for the Treatment of Primary and Metastatic Lung Tumors: Identification of Risk Factors for Recurrence and Major Complications. J Vasc Interv Radiol. 27(9):1371–1379PubMed

76.

Wang Y, Li G, Li W, He X, Xu L (2015) Radiofrequency ablation of advanced lung tumors: imaging features, local control, and follow-up protocol. Int J Clin Exp Med. 8(10):18137–18143PubMedPubMedCentral

77.

de Baere T, Auperin A, Deschamps F et al (2015) Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol. 26(5):987–991

78.

Yamauchi Y, Izumi Y, Hashimoto K et al (2012) Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer. PLoS One. 7(3):e33223

79.

Ambrogi MC, Fanucchi O, Cioni R et al (2011) Long-term results of radiofrequency ablation treatment of stage I non-small cell lung cancer: a prospective intention-to-treat study. J Thorac Oncol. 6(12):2044–2051

80.

Ito N, Nakatsuka S, Inoue M et al (2012) Computed tomographic appearance of lung tumors treated with percutaneous cryoablation. J Vasc Interv Radiol. 23(8):1043–1052

81.

Chaudhry A, Grechushkin V, Hoshmand M et al (2015) Characteristic CT Findings After Percutaneous Cryoablation Treatment of Malignant Lung Nodules. Medicine (Baltimore). 94(42):e1672

82.

Chou HP, Chen CK, Shen SH et al (2015) Percutaneous cryoablation for inoperable malignant lung tumors: midterm results. Cryobiology. 70(1):60–65

83.

Yang X, Ye X, Zheng A et al (2014) Percutaneous microwave ablation of stage I medically inoperable non-small cell lung cancer: clinical evaluation of 47 cases. J Surg Oncol. 110(6):758–763

84.

Zhong L, Sun S, Shi J et al (2017) Clinical analysis on 113 patients with lung cancer treated by percutaneous CT-guided microwave ablation. J Thorac Dis. 9(3):590–597

85.

Iguchi T, Hiraki T, Gobara H et al (2015) Percutaneous radiofrequency ablation of lung cancer presenting as ground-glass opacity. Cardiovasc Intervent Radiol. 38(2):409–415

86.

Nour-Eldin NE, Naguib NN, Tawfik AM, Gruber-Rouh T, Zangos S, Vogl TJ (2014) CT volumetric assessment of pulmonary neoplasms after radiofrequency ablation: when to consider a second intervention? J Vasc Interv Radiol. 25(3):347–354PubMed

87.

Cheng M, Fay M, Steinke K (2016) Percutaneous CT-guided thermal ablation as salvage therapy for recurrent non-small cell lung cancer after external beam radiotherapy: A retrospective study. Int J Hyperthermia. 32(3):316–323PubMed

88.

Han X, Yang X, Ye X J et al (2015) Computed tomography-guided percutaneous microwave ablation of patients 75 years of age and older with early-stage nonsmall cell lung cancer. Indian J Cancer. 52(Suppl 2):e56–e60

89.

Sharma A, Digumarthy SR, Kalra MK, Lanuti M, Shepard JA (2010) Reversible locoregional lymph node enlargement after radiofrequency ablation of lung tumors. AJR Am J Roentgenol. 194(5):1250–1256PubMed

90.

Izaaryene J, Vidal V, Bartoli JM, Loundou A, Gaubert JY (2017) Role of dual-energy computed tomography in detecting early recurrences of lung tumors treated with radiofrequency ablation. Int J Hyperthermia. 33(6):653–658PubMed

91.

Parvizi N, Chung D, Little MW, Gleeson FV, Anderson EM (2016) Does perfusion CT play a role in the evaluation of percutaneous microwave-ablated lung tumors? Clin Radiol. 71(11):1137–1142PubMed

92.

Alafate A, Shinya T, Okumura Y et al (2013) The Maximum standardized uptake value is more reliable than size measurement in early follow-up to evaluate potential pulmonary malignancies following radiofrequency ablation. Acta Med Okayama. 67(2):105–112

93.

Higaki F, Okumura Y, Sato S et al (2008) Preliminary retrospective investigation of FDG-PET/CT timing in follow-up of ablated lung tumor. Ann Nucl Med. 22(3):157–163

94.

LoGiurato B, Matthews R, Safaie E et al (2015) 18F-FDG PET-CT: predicting recurrence in patients following percutaneous cryoablation treatment for stage I primary non-small-cell lung cancer. Nucl Med Commun. 36(9):908–913

95.

Singnurkar A, Solomon SB, Gonen M, Larson SM, Schoder H (2010) 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions. J Nucl Med. 51(12):1833–1840PubMed

96.

Suzawa N, Yamakado K, Takao M, Taguchi O, Yamada T, Takeda K (2013) Detection of local tumor progression by (18)F-FDG PET/CT following lung radiofrequency ablation: PET versus CT. Clin Nucl Med. 38(4):e166–e170PubMed

97.

Bonichon F, Palussiere J, Godbert Y et al (2013) Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicenter prospective study. Eur J Nucl Med Mol Imaging. 40(12):1817–1827

98.

Sharma A, Lanuti M, He W, Palmer EL, Shepard JA, Digumarthy SR (2013) Increase in fluorodeoxyglucose positron emission tomography activity following complete radiofrequency ablation of lung tumors. J Comput Assist Tomogr. 37(1):9–14PubMed

99.

Chen J, Lin ZY, Wu ZB, Chen ZW, Chen YP (2017) Magnetic resonance imaging evaluation after radiofrequency ablation for malignant lung tumors. J Cancer Res Ther. 13(4):669–675PubMed

100.

Roman A, Kaltenbach B, Gruber-Rouh T, Naguib NN, Vogl TJ, Nour-Eldin NA (2018) The role of MRI in the early evaluation of lung microwave ablation. Int J Hyperthermia. 34(6):883–890PubMed

101.

Okuma T, Matsuoka T, Yamamoto A, Hamamoto S, Nakamura K, Inoue Y (2009) Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumors by diffusion-weighted MRI: a pilot study. Br J Radiol. 82(984):989–994PubMedPubMedCentral

102.

Staal F, Taghavi M, Imani F et al (2019) CT texture analyses of colorectal liver metastases before and after thermal ablation can predict local tumor progression. Insights Imaging 10(Suppl 2):20

103.

Maas M, Rutten IJ, Nelemans PJ et al (2011) What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis : imaging for recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 38(8):1560–1571

104.

Gavanier M, Ayav A, Sellal C et al (2016) CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1. Eur J Radiol. 85(1):103–112

105.

Ronot M, Bouattour M, Wassermann J et al (2014) Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist. 19(4):394–402

106.

Weng Z, Ertle J, Zheng S et al (2013) Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma. Oncol Lett. 6(6):1707–1712

107.

Chaudhry M, McGinty K, Mervak B et al (2020) The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma. Radiology. 294(2):320–326

Title: Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice
Authors: Monique Maas
Regina Beets-Tan
Jean-Yves Gaubert
Fernando Gomez Munoz
Paul Habert
Lisa G. Klompenhouwer
Paulo Vilares Morgado
Niklaus Schaefer
Francois H. Cornelis
Stephen B. Solomon
Denise van der Reijd
Jose Ignacio Bilbao
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keywords: Lung Cancer
Lung Cancer
Interventional Radiology
Hepatocellular Carcinoma
Hepatocellular Carcinoma
Lung Cancer
Renal Cancer
Published in: Insights into Imaging / Issue 1/2020
Electronic ISSN: 1869-4101
DOI: https://doi.org/10.1186/s13244-020-00884-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Artificial intelligence abstracts from the European Congress of Radiology: analysis of topics and compliance with the STARD for abstracts checklist

Effects of Rex-bypass shunt on the cavernous transformation of the portal vein in children: evaluation by the color Doppler ultrasonography

The identity and role of the radiologist in 2020: a survey among ESR full radiologist members

Imaging diagnosis of metastatic breast cancer

Radiology in the era of value-based healthcare: a multi-society expert statement from the ACR, CAR, ESR, IS3R, RANZCR, and RSNA

Adenocarcinoma of the lung: from BAC to the future